JP2017534644A - 抗ａｎｇ２抗体及び使用方法 - Google Patents

抗ａｎｇ２抗体及び使用方法 Download PDF

Info

Publication number
JP2017534644A
JP2017534644A JP2017525007A JP2017525007A JP2017534644A JP 2017534644 A JP2017534644 A JP 2017534644A JP 2017525007 A JP2017525007 A JP 2017525007A JP 2017525007 A JP2017525007 A JP 2017525007A JP 2017534644 A JP2017534644 A JP 2017534644A
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
acid sequence
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017525007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534644A5 (cg-RX-API-DMAC7.html
Inventor
デングル，シュテファン
ヒュールスマン，ペーター・ミヒャエル
ジョルジュ，ギー
ケッテンベルガー，フーベルト
レグラ，イェルク・トーマス
モルケン，イェルク
モルホイ，ミヒャエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2017534644A publication Critical patent/JP2017534644A/ja
Publication of JP2017534644A5 publication Critical patent/JP2017534644A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017525007A 2014-11-10 2015-11-06 抗ａｎｇ２抗体及び使用方法 Pending JP2017534644A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192524.8 2014-11-10
EP14192524 2014-11-10
PCT/EP2015/075876 WO2016075035A1 (en) 2014-11-10 2015-11-06 Anti-ang2 antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020205947A Division JP2021050229A (ja) 2014-11-10 2020-12-11 抗ａｎｇ２抗体及び使用方法

Publications (2)

Publication Number Publication Date
JP2017534644A true JP2017534644A (ja) 2017-11-24
JP2017534644A5 JP2017534644A5 (cg-RX-API-DMAC7.html) 2018-12-06

Family

ID=51868115

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017525007A Pending JP2017534644A (ja) 2014-11-10 2015-11-06 抗ａｎｇ２抗体及び使用方法
JP2020205947A Pending JP2021050229A (ja) 2014-11-10 2020-12-11 抗ａｎｇ２抗体及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020205947A Pending JP2021050229A (ja) 2014-11-10 2020-12-11 抗ａｎｇ２抗体及び使用方法

Country Status (14)

Country Link
US (1) US10538585B2 (cg-RX-API-DMAC7.html)
EP (1) EP3218398A1 (cg-RX-API-DMAC7.html)
JP (2) JP2017534644A (cg-RX-API-DMAC7.html)
KR (1) KR20170082594A (cg-RX-API-DMAC7.html)
CN (1) CN107001456A (cg-RX-API-DMAC7.html)
AR (1) AR102595A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015345321A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017009790A2 (cg-RX-API-DMAC7.html)
CA (1) CA2963606A1 (cg-RX-API-DMAC7.html)
IL (1) IL251477A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017005642A (cg-RX-API-DMAC7.html)
SG (1) SG11201703458UA (cg-RX-API-DMAC7.html)
TW (1) TW201630935A (cg-RX-API-DMAC7.html)
WO (1) WO2016075035A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021508452A (ja) * 2017-12-22 2021-03-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 疎水性相互作用クロマトグラフィーによる軽鎖誤対合抗体変種の枯渇の方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537100T3 (es) 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecíficos trivalentes
JP6946184B2 (ja) 2014-11-10 2021-10-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｐｄｇｆ−ｂ抗体及び使用法
WO2016075034A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
KR20170080584A (ko) 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
JP2023530187A (ja) 2020-06-22 2023-07-13 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ａｎｇ－２抗体とその用途
US20230312698A1 (en) * 2020-08-07 2023-10-05 Nanjing GenScript Biotech Co., Ltd. Antibodies against human angiopoietin-2 and uses thereof
CA3192239A1 (en) * 2020-08-19 2022-02-24 Pharmabcine Inc. Modified antibody and method for manufacturing same
CN115772544B (zh) * 2021-09-06 2024-04-26 合肥星眸生物科技有限公司 抗vegf-a和ang-2的aav载体
CN116925234B (zh) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体
CN117820490A (zh) * 2022-09-28 2024-04-05 科兴生物制药股份有限公司 Vegf和ang-2双特异性抗体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506510A (ja) * 2007-12-21 2011-03-03 エフ．ホフマン−ラ ロシュ アーゲー ２価二重特異性抗体
JP2012504943A (ja) * 2008-10-08 2012-03-01 エフ．ホフマン−ラ ロシュ アーゲー 二重特異的抗−ｖｅｇｆ／抗−ａｎｇ−２抗体
WO2014009465A1 (en) * 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
JP2014509857A (ja) * 2011-03-16 2014-04-24 アムジエン・インコーポレーテツド Ｆｃ変異体
WO2014177460A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
AU2003208946A1 (en) 2002-02-28 2003-09-16 Eli Lilly And Company Anti-interleukin-1 beta analogs
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
CA2509136C (en) 2003-01-24 2013-10-29 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP2703011A3 (en) 2007-05-07 2014-03-26 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2727171A1 (en) 2008-06-06 2009-12-10 Xoma Technology Ltd. Methods for the treatment of rheumatoid arthritis
RU2368359C1 (ru) 2008-07-22 2009-09-27 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ лечения возрастной макулярной дегенерации
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
MX2013001267A (es) 2010-08-13 2013-04-10 Genentech Inc ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
RU2013115927A (ru) 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
JP6069312B2 (ja) * 2011-06-29 2017-02-01 アムジェン インコーポレイテッド 腎細胞癌の治療における生存の予測バイオマーカー
EP2867360B1 (en) 2012-06-28 2019-05-08 Molecular Partners AG Designed ankyrin repeat proteins binding to platelet-derived growth factor
CN104661678A (zh) * 2012-09-28 2015-05-27 勃林格殷格翰国际有限公司 包含双重血管生成素-2/Dll4结合物和抗VEGF-R药剂的药物组合
KR20150060686A (ko) * 2012-09-28 2015-06-03 베링거 인겔하임 인터내셔날 게엠베하 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF 제제를 포함하는 약제학적 조합물
BR112015010566A2 (pt) 2012-11-08 2017-07-11 Clearside Biomedical Inc métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
EP2917237A1 (en) 2012-11-09 2015-09-16 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
PE20160753A1 (es) * 2013-12-20 2016-08-01 Hoffmann La Roche Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
RU2727639C2 (ru) * 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
JP6946184B2 (ja) 2014-11-10 2021-10-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｐｄｇｆ−ｂ抗体及び使用法
KR20170080584A (ko) * 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
WO2016075034A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
US20190004048A1 (en) * 2015-06-26 2019-01-03 Amgen Inc. Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor
US11198726B2 (en) * 2017-06-02 2021-12-14 Boerhinger Ingelheim International Gmbh Anti-cancer combination therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506510A (ja) * 2007-12-21 2011-03-03 エフ．ホフマン−ラ ロシュ アーゲー ２価二重特異性抗体
JP2012504943A (ja) * 2008-10-08 2012-03-01 エフ．ホフマン−ラ ロシュ アーゲー 二重特異的抗−ｖｅｇｆ／抗−ａｎｇ−２抗体
JP2014509857A (ja) * 2011-03-16 2014-04-24 アムジエン・インコーポレーテツド Ｆｃ変異体
WO2014009465A1 (en) * 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2014177460A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KYRIAKOS P. PAPADOPOULOS, A PHASE I FIRST-IN-HUMAN STUDY OF REGN910 (SAR307746), A FULLY HUMAN AND S, JPN5018000283, ISSN: 0004123645 *
PLOS ONE (2013) VOL.8, NO,2, E54923, PP.1-11, JPN6019037527, ISSN: 0004123646 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021508452A (ja) * 2017-12-22 2021-03-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 疎水性相互作用クロマトグラフィーによる軽鎖誤対合抗体変種の枯渇の方法
JP7074859B2 (ja) 2017-12-22 2022-05-24 エフ．ホフマン－ラ ロシュ アーゲー 疎水性相互作用クロマトグラフィーによる軽鎖誤対合抗体変種の枯渇の方法

Also Published As

Publication number Publication date
US20170247441A1 (en) 2017-08-31
AU2015345321A1 (en) 2017-04-20
KR20170082594A (ko) 2017-07-14
IL251477A0 (en) 2017-05-29
AR102595A1 (es) 2017-03-08
CN107001456A (zh) 2017-08-01
JP2021050229A (ja) 2021-04-01
TW201630935A (zh) 2016-09-01
BR112017009790A2 (pt) 2017-12-19
SG11201703458UA (en) 2017-05-30
WO2016075035A1 (en) 2016-05-19
MX2017005642A (es) 2017-07-24
US10538585B2 (en) 2020-01-21
EP3218398A1 (en) 2017-09-20
CA2963606A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
JP7240443B2 (ja) Ｆｃ受容体結合が変更された非対称抗体および使用方法
US10538585B2 (en) Anti-ANG2 antibodies and methods of use
JP7077263B2 (ja) 二重特異性ｈｅｒ２抗体及び使用方法
CN107148429B (zh) 抗-pdgf-b抗体和使用方法
EP3313890A1 (en) Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
CN107074941A (zh) 双特异性抗体和用于眼科学的方法
HK1241384A1 (en) Anti-ang2 antibodies and methods of use
HK1239711A1 (en) Anti-pdgf-b antibodies and methods of use
HK1239711B (zh) 抗-pdgf-b抗体和使用方法
HK1236207A1 (en) Bispecific antibodies and methods of use in ophthalmology

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200811